ICU care of patients considered "palliative" but without contraindications to admission to intensive care, for whom a do-not intubate order decision was made upon admission represents a particular target for non-invasive oxygenation techniques. The benefits of non invasive ventilation (NIV) in this population are debated especially in cancer patients. The more recently used nasal humidified high flux canula oxygenation (HFNC) therapy may have benefits over NIV in these patients. It is supposed to have better tolerance and could allow better compliance and thus higher efficiency. These potential benefits are major for such a population for which tolerance and symptomatic relief are priority goals
Observational prospective multicenter study Primary outcome: To analyze the efficacy and tolerance of NIV and HFNC in patients admitted to intensive care unit, or intermediate catre unit for acute respiratory insufficiency for whom a a do-not intubate order decision was taken upon admission or after extubation if the patient initially received mechanical ventilation. Secondary outcomes: To analyze the efficacy and tolerance of NIV and HFNC according to the following reason for ICU admission: chronic obstructive pneumopathy decompensated COPD, severe heart failure, evolutive cancer or hematologic malignancy; to analyze tolerance and acceptability of different techniques; to analyze the duration of the oxygenation methods use; to analyze the modalities of eventual withdrawing life support therapies and the associated sedative and opioid treatments; to analyze the satisfaction for the use of the non invasive technique by the relatives and the caregivers; to analyze mortality at D28 and D90 and quality of life at 3 and 6 months in surviving patients
Study Type
OBSERVATIONAL
Enrollment
330
Chu de Poitiers
Poitiers, France
RECRUITINGSurvival at day 14
Survival at day 14 in patients weaned from NIV and or HNFC-O2
Time frame: day 14
Clinical respiratory parameters evolution
respiratory rate improvement will be assessed by a decrease of respiratory rate below 20/min
Time frame: day 1, day 2, day 3
Oxygenation parameters evolution
sPO2 (oxygen saturation) expressed in % improvement will be assessed by an increase above 92%
Time frame: day 1, day 2, day 3
tolerance of technique of oxygenation
tolerance will be assessed by comfort visual analogic scale from 1 worse tolerance to 10 very good tolerance; improvement defined as a 20% decrease of the value
Time frame: day 1, day 2, day 3
evolution of quality of life
quality of life will be measured by the EuroQuality of life 5D score (EQ5D) recording 5 subscore (mobility, autonomy, ability to perform current activities, pain, anxety/depression); the value of each is from 1 to 3 points; total score is the sum of the 5 subscores with a minimal score of 5 and a maximal score of 15. The baseline score will be recorded after admission in the ICU and reflects the patient's quality of life just before his or her admission. After 3 and 6 months, a higher value of the score will represent a worse outcome.
Time frame: on admission and after 3 and 6 months after ICU stay
Acceptation of the non invasive technique
tolerance defined by the absence of refusal to continue the technique (NIV or HNFC O2) by the patient
Time frame: day 14
mortality day 28
percentage of patients deceased at day 28 whatever the cause of death
Time frame: day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.